Literature DB >> 11482579

Bcl-2 correlates with tumor ploidy and nuclear morphology in early stage prostate carcinoma. A fine needle aspiration biopsy study.

M V Maffini1, H H Ortega, C Stoker, R H Giardina, E H Luque, M M Muñoz de Toro.   

Abstract

We evaluated the nuclear morphology, ploidy, bcl-2 expression and in situ apoptosis in sections of fine-needle aspiration (FNA) biopsy specimens of thirty-one randomly selected Stage B prostate carcinomas. Sections of paraffin-embedded pelleted cells obtained from FNA biopsy specimens were studied. Nuclear grade was determined according to the WHO system. Nuclear morphometry and DNA ploidy were carried out using an automated image analyzer. We used immunostaining and the TUNEL method to evaluate bcl-2 expression and in situ apoptosis. The median nuclear area increased with increasing nuclear grade. Ploidy analysis showed that 54.8% of tumors were diploid, 3.2% tetraploid and 41.9% aneuploid. Bcl-2 overexpression was found in 10 of 31 tumors. There was a significant positive correlation between bcl-2 expression and nuclear area (r(s): 0.45 p < 0.01). Nine of ten bcl-2-positive tumors had a nuclear area larger than the median of the series, and 70% of bcl-2-positive tumors were of the aneuploid type. The apoptotic index had a negative correlation with nuclear area, and the lowest indexes were found in aneuploid tumors. Bcl-2 expression showed a highly significant association with both parameters of high aggressiveness: nuclear size and aneuploidy. The combined evaluation of nuclear morphology, ploidy and cell survival parameters might better identify patients with poor prognosis among early stage prostate carcinomas diagnosed by FNA biopsies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11482579     DOI: 10.1078/0344-0338-00116

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

1.  Induction of mammary gland ductal hyperplasias and carcinoma in situ following fetal bisphenol A exposure.

Authors:  Tessa J Murray; Maricel V Maffini; Angelo A Ucci; Carlos Sonnenschein; Ana M Soto
Journal:  Reprod Toxicol       Date:  2006-10-24       Impact factor: 3.143

2.  Dual regulation of breast tubulogenesis using extracellular matrix composition and stromal cells.

Authors:  Silva Krause; Adeline Jondeau-Cabaton; Eugen Dhimolea; Ana M Soto; Carlos Sonnenschein; Maricel V Maffini
Journal:  Tissue Eng Part A       Date:  2011-12-02       Impact factor: 3.845

3.  Relaxin has a minor role in rat mammary gland growth and differentiation during pregnancy.

Authors:  L Kass; J G Ramos; H H Ortega; G S Montes; L E Bussmann; E H Luque; M Muñoz de Toro
Journal:  Endocrine       Date:  2001-08       Impact factor: 3.633

4.  The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures.

Authors:  Silva Krause; Maricel V Maffini; Ana M Soto; Carlos Sonnenschein
Journal:  BMC Cancer       Date:  2010-06-07       Impact factor: 4.430

5.  Hypoxia and defective apoptosis drive genomic instability and tumorigenesis.

Authors:  Deirdre A Nelson; Ting-Ting Tan; Arnold B Rabson; Diana Anderson; Kurt Degenhardt; Eileen White
Journal:  Genes Dev       Date:  2004-08-16       Impact factor: 11.361

6.  Hormonal regulation of epithelial organization in a three-dimensional breast tissue culture model.

Authors:  Lucia Speroni; Gregory S Whitt; Joanna Xylas; Kyle P Quinn; Adeline Jondeau-Cabaton; Clifford Barnes; Irene Georgakoudi; Carlos Sonnenschein; Ana M Soto
Journal:  Tissue Eng Part C Methods       Date:  2013-06-25       Impact factor: 3.056

7.  Quantitative pathology: historical background, clinical research and application of nuclear morphometry and DNA image cytometry.

Authors:  Abdelbaset Buhmeida
Journal:  Libyan J Med       Date:  2006-09-20       Impact factor: 1.657

8.  Prognostic factors in prostate cancer.

Authors:  A Buhmeida; S Pyrhönen; M Laato; Y Collan
Journal:  Diagn Pathol       Date:  2006-04-03       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.